SAB BIO to Participate in Upcoming Investor Conferences

SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical firm focused on the development of human anti-thymocyte immunoglobulin (hATG), has announced the participation of its management team in several upcoming investor conferences this November and December. The company is working on innovative therapies for autoimmune diseases, specifically targeting the delay of type 1 diabetes (T1D) progression in new onset Stage 3 patients.

The scheduled conferences include the UBS Global Healthcare Conference on November 10, 2025, where the team will engage in a fireside chat at 2:45 p.m. ET in West Palm Beach, FL. On November 12, 2025, the management will also present at the Guggenheim Second Annual Healthcare Innovation Conference at 10:00 a.m. ET in Boston, MA, followed by participation in the 8th Annual Evercore Healthcare Conference on December 2, 2025, at 3:50 p.m. ET in Coral Gables, FL. Interested parties can access live webcasts of the events and archived recordings through the Investor Relations section on the company’s website, www.sab.bio.

SAB BIO's flagship product, SAB-142, represents a potentially transformative approach to treating autoimmune T1D by modifying the disease trajectory. The company leverages advanced genetic engineering techniques involving transchromosomic cattle (Tc Bovine) to produce high-potency human immunoglobulin G (hIgG). This proprietary platform allows SAB BIO to generate multiple therapeutic candidates that target a variety of severe unmet medical needs, offering promising advancements in the management of immune and autoimmune disorders. For further details, investors and media can reach out via the provided email contacts.

SAB Biotherapeutics, Inc. (Nasdaq: SABS) is strategically positioning itself for increased visibility and investor interest by participating in several notable healthcare conferences this November and December. This initiative comes at a pivotal time for the company as it continues to advance its clinical-stage product pipeline, particularly its lead therapeutic candidate, SAB-142, aimed at managing type 1 diabetes (T1D) progression.

Participation in conferences such as the UBS Global Healthcare Conference and the Guggenheim Second Annual Healthcare Innovation Conference offers SAB BIO a critical platform to communicate its innovative approaches, particularly the advanced genetic engineering behind its proprietary human immunoglobulin (hIgG) therapies. Investors should closely monitor the insights shared during these fireside chats, as they could provide significant validation of SAB BIO's business model and future market potential.

The focus on T1D, especially in new onset Stage 3 patients, addresses a significant and growing unmet medical need, thereby expanding the company’s relevance within the biopharmaceutical sector. As diabetes prevalence rises, a reliable solution like SAB-142 could capture considerable market share, benefitting early investors.

Moreover, the utilization of transchromosomic cattle technology allows SAB BIO to differentiate itself technologically from competitors, a narrative that is likely to resonate well with institutional investors seeking innovative biotech investments. Given the timing of these conferences—early November leading into year-end—this is an opportune moment for investors to assess the company's positioning and the market's perception.

In conclusion, investors should consider adding SAB BIO to their watchlist as the company ramps up its engagement with the investment community. Staying tuned to the outcomes of these conferences could provide critical insights into SAB BIO's operational transparency, clinical progress, and overall growth trajectory in the coming months.